Literature DB >> 19229289

Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters.

S Bortolanza1, M Bunuales, P Alzuguren, O Lamas, R Aldabe, J Prieto, R Hernandez-Alcoceba.   

Abstract

A partial deletion of the adenovirus E3 region, comprising the overlapping 6.7K/gp19K genes, has been described for the incorporation of therapeutic genes in 'armed' oncolytic adenoviruses. This deletion allows the insertion of up to 2.5 kb genetic material into the virus and ensures strong expression of transgenes without reducing the replication and cytolytic potency of viruses in vitro. E3-gp19K and 6.7K proteins are involved in avoiding recognition and elimination of infected cells by the host immune system. Therefore, we have studied the effect of this deletion on the replication and transgene expression of the virus in immunocompetent models based on Syrian hamsters. Tumors were established by intrahepatic injection of pancreatic cancer cells with moderate (HaP-T1, HP-1) or low (H2T) permissivity for adenovirus replication. The wild-type human adenovirus 5 (Ad5) or a modified version containing the luciferase gene in the E3-6.7K/gp19K locus (Ad-WTLuc) were injected intratumorally. We found that elimination of Ad-WTLuc was faster than Ad5 in HaP-T1 and HP-1 tumors. In contrast, no differences were observed when the same tumor was established in severely immunocompromised NOD-scid IL2Rgamma(null) mice. In addition, virus-mediated luciferase expression was more stable in these animals. These results suggest that the lack of E3-6.7K/gp19K genes may accelerate the clearance of oncolytic adenoviruses in some immunocompetent tumor models.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19229289     DOI: 10.1038/cgt.2009.12

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  15 in total

1.  Safety and antitumor effect of oncolytic and helper-dependent adenoviruses expressing interleukin-12 variants in a hamster pancreatic cancer model.

Authors:  J Poutou; M Bunuales; M Gonzalez-Aparicio; E Garcia-Aragoncillo; J I Quetglas; R Casado; C Bravo-Perez; P Alzuguren; R Hernandez-Alcoceba
Journal:  Gene Ther       Date:  2015-05-04       Impact factor: 5.250

2.  Adenovirus i-leader truncation bioselected against cancer-associated fibroblasts to overcome tumor stromal barriers.

Authors:  Cristina Puig-Saus; Alena Gros; Ramon Alemany; Manel Cascalló
Journal:  Mol Ther       Date:  2011-08-23       Impact factor: 11.454

3.  Pathology in Permissive Syrian Hamsters after Infection with Species C Human Adenovirus (HAdV-C) Is the Result of Virus Replication: HAdV-C6 Replicates More and Causes More Pathology than HAdV-C5.

Authors:  Ann E Tollefson; Baoling Ying; Jacqueline F Spencer; John E Sagartz; William S M Wold; Karoly Toth
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

4.  The combination of i-leader truncation and gemcitabine improves oncolytic adenovirus efficacy in an immunocompetent model.

Authors:  C Puig-Saus; E Laborda; A Rodríguez-García; M Cascalló; R Moreno; R Alemany
Journal:  Cancer Gene Ther       Date:  2014-01-17       Impact factor: 5.987

5.  Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.

Authors:  Han Hsi Wong; Nicholas R Lemoine; Yaohe Wang
Journal:  Viruses       Date:  2010-01       Impact factor: 5.818

6.  Second-generation HIF-activated oncolytic adenoviruses with improved replication, oncolytic, and antitumor efficacy.

Authors:  T Cherry; S L Longo; Z Tovar-Spinoza; D E Post
Journal:  Gene Ther       Date:  2010-07-22       Impact factor: 5.250

7.  Evaluation of monocytes as carriers for armed oncolytic adenoviruses in murine and Syrian hamster models of cancer.

Authors:  Maria Bunuales; Eva Garcia-Aragoncillo; Raquel Casado; José Ignacio Quetglas; Sandra Hervas-Stubbs; Sergia Bortolanza; Carolina Benavides-Vallve; Carlos Ortiz-de-Solorzano; Jesus Prieto; Ruben Hernandez-Alcoceba
Journal:  Hum Gene Ther       Date:  2012-10-26       Impact factor: 5.695

8.  Complete genome analysis of a novel E3-partial-deleted human adenovirus type 7 strain isolated in Southern China.

Authors:  Xiaobo Su; Xingui Tian; Qiwei Zhang; Haitao Li; Xiao Li; Huiying Sheng; Youshao Wang; Houbo Wu; Rong Zhou
Journal:  Virol J       Date:  2011-03-04       Impact factor: 4.099

Review 9.  Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer.

Authors:  Anwen Howells; Giulia Marelli; Nicholas R Lemoine; Yaohe Wang
Journal:  Front Oncol       Date:  2017-09-08       Impact factor: 6.244

Review 10.  Effect of Transgene Location, Transcriptional Control Elements and Transgene Features in Armed Oncolytic Adenoviruses.

Authors:  Martí Farrera-Sal; Cristina Fillat; Ramon Alemany
Journal:  Cancers (Basel)       Date:  2020-04-23       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.